Clinical trials: Cannabis Use Disorder
Cannabis Dependence
Gabapentin Treatment of Cannabis Dependence
This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.
- Trial name
- NCT00395044
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Scripps Research Institute
Cannabis Use Disorder
A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder
This investigation will preliminarily determine if a course of high-frequency rTMS applied to the left dorsolateral prefrontal cortex, will reduce behavioral craving, and fMRI cue-reactivity in treatment-seeking cannabis use…
- Trial name
- NCT03144232
- Testing
- Active rTMS
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Stanford University
Cannabis Dependence, Alcohol Dependence
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
The primary aim of the supplemental study is to provide POC testing of aprepitant as a treatment for comorbid alcohol and cannabis dependence.
- Conditions
- Cannabis Dependence, Alcohol Dependence, Cannabis Use Disorder, Alcohol Use Disorder
- Trial name
- NCT02210195
- Testing
- aprepitant, Manual-guided behavioral counseling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Scripps Research Institute
Cannabis Use Disorder, Cannabis Withdrawal
Progesterone for Cannabis Withdrawal
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options.
- Trial name
- NCT03430050
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Dual Diagnosis
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment
The first aim of this study is to determine whether a brain reward center (BRC) deficiency in patients with schizophrenia (SCZ) and cannabis use disorder (CUD) will be normalized when patients are given cannabis or dronabinol.
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00946348
- Testing
- Dronabinol, Cannabis
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cannabis, Cannabis Use
Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase)
Nearly 20 million Americans report use of cannabis in the past month, and heavy cannabis use has increased by nearly 60% in the U.S. since 2007.
- Trial name
- FOCUS (NCT04567238)
- Testing
- Mobile contingency management
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Schizophrenia
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or seen by others) or delusions…
- Trial name
- NCT01832766
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Bipolar Disorder, Cannabis-Related Disorder
Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania
The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.
- Trial name
- NCT00393978
- Testing
- Quetiapine and Topiramate
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Cincinnati
Cannabis Dependence, Marijuana Dependence
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
Cannabis use disorders are an important public health problem in the United States, but no effective pharmacotherapies are available to treat these disorders.
- Trial name
- DCCS (NCT01598896)
- Testing
- Dronabinol, Clonidine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mclean Hospital
Substance Use Disorder
Varenicline Treatment for Cannabis Use Disorder
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed.
- Trial name
- NCT02892110
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Multiple Sclerosis, Spasticity
A Study of the Long-term Safety of Sativex Use
Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
- Conditions
- Multiple Sclerosis, Spasticity, Pain
- Trial name
- NCT01606137
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 507 people
- Sponsor
- Jazz Pharmaceuticals
Cannabis Use Disorder
Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder
Investigators aim to determine Epidiolex's promise as a pharmacotherapy for cannabis use disorder. Investigators hypothesize that Epidiolex, when added to medical management, will result in greater reductions in marijuana use…
- Trial name
- CBD (NCT03102918)
- Testing
- Cannabidiol
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Type 2 Diabetes, Obesity
Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
This study tests the effects of cannabinoid levels in blood on inflammation and insulin sensitivity both acutely and chronically in individuals across the weight spectrum.
- Conditions
- Type 2 Diabetes, Obesity, Cannabis Use, Insulin Sensitivity
- Trial name
- SONIC (NCT04114903)
- Testing
- Study A: Single use of cannabis flower product, Study B: Ad libitum cannabis use for four weeks or no cannabis use
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- University of Colorado, Boulder
Marijuana Use Disorder
Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks
The purpose of this study is to investigate the effects of smoked marijuana on both risk taking and decision making tasks.
- Trial name
- NCT00373399
- Testing
- Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Cannabis Dependence, Marijuana Dependence
Nabilone for Cannabis Dependence: A Pilot Study
Cannabis use disorders are an important public health problem in the United States, but there are no effective medications available to treat these disorders.
- Trial name
- NAB CAN (NCT01347762)
- Testing
- Nabilone
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mclean Hospital
Psychosis, Substance Use
Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) and Substance Use: A Pilot Study
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth…
- Conditions
- Psychosis, Substance Use, Substance Use Disorders, Family
- Trial name
- NCT05380583
- Testing
- CRAFT-EP, TAU
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Cannabis Use Disorder
UH3 Varenicline for Cannabis Use Disorder
Marijuana is the most commonly used illicit drug. There is high demand for effective interventions for cannabis use disorder, yet few specific treatments for have been developed.
- Trial name
- NCT03980561
- Testing
- Varenicline
- Where
- 2 sites in United States
- Volunteers
- 174 people
- Sponsor
- Medical University of South Carolina
Insomnia, Alcohol Use, Unspecified
Research Evaluating Sleep & Trends for Universal Prevention
This study is designed to develop an integrated intervention to reduce alcohol and marijuana use and consequences and improve sleep among young adults with comorbid heavy episodic drinking, marijuana use, and sleep impairment.
- Conditions
- Insomnia, Alcohol Use, Unspecified, Marijuana Use
- Trial name
- REST-UP (NCT04783519)
- Testing
- Brief Behavioral Therapy for Insomnia (BBTI), Brief Alcohol Screening and Intervention for College Students (BASICS)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Washington
Marijuana Abuse, Sleep Initiation and Maintenance Disorders
CBT-I for Cannabis Use
The purpose of this study is to investigate the efficacy of a group-based behavioral sleep intervention, and the incremental benefit provided by an adjunct sleep mobile app, on cannabis and sleep outcomes among cannabis dependent…
- Trial name
- CBT-I-CU (NCT02102230)
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA), Desensitization Treatment for Insomnia
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- VA Office of Research and Development